Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 7/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14568570 | 0.85 | CCR4 (0.47) | CCR4CACNA2D1KCNH3 | |
| SCHEMBL5504231 | 0.83 | CCR4 (0.43) | CCR4CACNA2D1SLC2A1KCNH3 | |
| SCHEMBL5490179 | 0.83 | CCR4 (0.43) | CCR4CACNA2D1SLC2A1KCNH3 | |
| SCHEMBL14569082 | 0.83 | CCR4 (0.43) | CCR4CACNA2D1SLC2A1KCNH3 | |
| SCHEMBL5498051 | 0.82 | CCR4 (0.44) | CCR4CACNA2D1KCNH3 | |
| SCHEMBL5496656 | 0.77 | BRAF (0.46) | CCR4CACNA2D1SLC2A1KCNH3RPS6KB1 | |
| SCHEMBL5496328 | 0.77 | BRAF (0.46) | CCR4CACNA2D1SLC2A1KCNH3RPS6KB1 | |
| SCHEMBL5498963 | 0.77 | BRAF (0.46) | CCR4CACNA2D1SLC2A1KCNH3RPS6KB1 | |
| SCHEMBL5501587 | 0.77 | CCR4 (0.42) | CCR4CACNA2D1SLC2A1RPS6KB1 | |
| SCHEMBL14569086 | 0.76 | CCR4 (0.43) | CCR4CACNA2D1SLC2A1KCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | CCR4 980/4885CACNA2D1 4841/4885SLC2A1 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.